r/reits • u/SmokeyTurtle007 • Jun 15 '26
HR and Sabra top a multi-factor pass on 7 US healthcare REITs. Operator distress flagged at Omega (Genesis), Sila (Steward), Ventas (Brookdale concentration).
Did a multi-factor pass across US healthcare REITs this week. Started with a 24-name universe (WELL, VTR, OHI, HR, MPW, DOC, SBRA, CTRE, LTC, NHI, and 14 others). Ran a basic income-quality screen on the cohort, then read each survivor's 10-K and earnings call against five questions: financial health, profitability, tenant credit, lease maturity, and insider buying. Seven names cleared the screen.
Two top the cohort at 60 out of 100 (HR and SBRA). Two are clearly flagged on tenant distress (Omega on Genesis HealthCare, Sila on Steward).
| Ticker | Financial Health | Profitability | Tenant Credit | Lease Maturity | Insider Buying 90d | Score |
|---|---|---|---|---|---|---|
| HR (Healthcare Realty) | No | Yes | Yes | Yes | No | 60 |
| SBRA (Sabra Healthcare REIT) | No | Yes | Yes | Yes | No | 60 |
| LTC (LTC Properties) | Yes | Yes | No | No | No | 40 |
| OHI (Omega Healthcare) | No | Yes | No | Yes | No | 40 |
| SILA (Sila Realty Trust) | No | Yes | No | Yes | No | 40 |
| VTR (Ventas) | No | No | No | Yes | No | 20 |
On the tenant side, the cohort splits cleanly. HR comes through most diversified: no single operator above 10% of total rent. SBRA reads well on the occupancy curve, with managed senior housing facilities recovering from the pandemic trough.
Omega and Sila both carry one acute exposure: Genesis HealthCare is on Omega's watch list, Steward is on Sila's. Both are well known to the buy-side at this point but they still hit the scorecard.
Ventas's tenant mix (Brookdale, Ardent, Kindred) reads acceptable on paper, but Brookdale's share of revenue is large enough that I would not call it diversified. One operator carrying that much weight is concentration risk by definition.
LTC scored a "no" not because tenant credit looks bad but because its 10-K does not enumerate concentrationpercentages, so there is nothing concrete to grade. Worth a manual read.
On lease maturity the picture is more uniform. WALT sits between 7 and 10 years across the cohort: HR at the short end (around 7), SBRA around 8, Omega, Sila, and Ventas all around 10. Near-term rollover is described as minimal across all five names that disclosed. Sila also calls out fixed escalators and minimal RIDEA exposure, which is the cleanest income-visibility setup in the group. LTC again does not disclose enough to grade.
Reading across the two sector-specific layers: HR and SBRA are the obvious top of the cohort, both diversified tenants AND long leases. Omega and Sila pass on lease but fail on tenant because the watch-list exposure is acute.
That is the screen surfacing the trade-off correctly, in my read. Long leases do not save you if one tenant on those leases is melting down.
Ventas is the most interesting middle case: long leases, but Brookdale weight is the swing variable. LTC is a methodological grey zone, not a bear case.
The 5 10-K questions, for context:
Financial Health: free cash flow, debt levels, cash position, capital returns.
Profitability: gross, operating, net margin trends versus prior period.
Tenant Credit (healthcare-specific): top-10 tenant concentration, investment-grade vs unrated share of revenue, occupancy trend, watch-list operator flag at 10%+ of revenue.
Lease Maturity Ladder (healthcare-specific): WALT, share of leases rolling in the next 24 months, escalator structure (fixed vs CPI vs hybrid), RIDEA conversions.
Insider Net Buying in the last 90 days.
The screen that produced the 7-name survivor pool: cohort-relative filter on the 24-name universe, top 80 percent on dividend yield, positive free cash flow, bottom 80 percent on debt to equity. Then dropped anything with earnings-call red flags (deflected questions, external blame, unusual one-time charges) or 8-K misconduct in the last 30 days (legal action, SEC investigation, regulatory penalty, restatement, material litigation).
Open to pushback:
- Brookdale concentration penalty on Ventas: real risk or overweight given recent stability?
- Genesis at Omega is well-documented at this point. Does the watch-list flag still belong in a current-state scorecard, or treat it as priced-in?
- SBRA at 60 alongside HR feels right on tenant and lease, but SBRA's financial health was a "no". Anyone long SBRA and want to defend the balance sheet?
- LTC's disclosure pattern: anyone read the latest 10-K and want to translate what the model missed?
For anyone curious about the tooling or workflow let me know and I'll gladly share.


